[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bangladesh Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":504},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,48,75,101,125,143,162,186,208,232,260,287,312,336,364,390,411,444,468,486],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100650591","zepu-ai9-exoskeleton-rehabilitation-robot-100650591",false,"NCT07750808","ZEPU AI9 Exoskeleton Rehabilitation Robot","Feasibility, Safety and Efficacy of ZEPU AI9 Lower Limb Exoskeleton Rehabilitation Robot in Patients With Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 60 years.\n* Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\> 3months post-surgery.\n* Able to provide informed consent and understand instructions.\n* Weight ≤ 100 kg (as per device spec) and height within device adjustable range (manufacturer spec).\n* Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, untreated DVT) with necessary investigations.\n\nExclusion Criteria:\n\n* Complete spinal cord injury with inability to bear any weight.\n* Severe cognitive impairment (e.g., MMSE \\\u003C 24) preventing safe participation.\n* Severe spasticity (Modified Ashworth Scale \\> 3) in lower limbs.\n* Unstable fractures, severe hip\u002Fknee contractures (\\> 30° fixed flexion), severe osteoarthritis requiring imminent surgery.\n* Uncontrolled cardiac arrhythmia, pacemaker incompatibility, or implanted electronic device incompatible with robot sensors.\n* Pregnancy.","ALL","18 Years","60 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether the ZEPU AI9 lower limb exoskeleton robot is feasible, safe, and effective for people with walking difficulty caused by stroke, incomplete spinal cord injury, or orthopedic surgery. The main questions it aims to answer are:\n\nIs exoskeleton-assisted gait training well tolerated, and how often do device-related problems (such as falls, pain, or skin injury) occur? Does adding exoskeleton training to usual rehabilitation improve walking distance, walking speed, balance, muscle strength, and joint movement compared with usual rehabilitation alone? Is it practical to add this robotic training into the rehabilitation program at Bangladesh Medical University?\n\nResearchers will compare a group receiving exoskeleton-assisted gait training plus standard rehabilitation to a group receiving standard rehabilitation alone, to see whether the exoskeleton adds benefit.\n\nParticipants will:\n\nBe randomly assigned to either the exoskeleton group or the standard-care group If assigned to the exoskeleton group, attend 45-minute training sessions 3 times a week for 12 weeks, supervised by physical therapists with safety harness support Both groups will continue their usual rehabilitation therapy throughout the study Undergo walking, balance, strength, and quality-of-life assessments at the start of the study and every 2 weeks for 12 weeks Be monitored for any side effects or safety concerns during and after each session",[27,28,29,30],"Stroke","Gait Disorders, Neurologic","Spinal Cord Injuries, Incomplete","Postoperative Complication",[32,33,34],"Lower limb exoskeleton","Robotic Rehabilitation","Neurorehabilitation","NOT_YET_RECRUITING","2026-08-06",{"date":38,"type":39},"2026-08-10","ACTUAL",{"date":41,"type":21},"2026-08",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"Bangladesh Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100650652","zepu-ai-series-limb-feedback-robot-training-study-zepuaisrct-100650652","NCT07749625","ZEPU-AI Series Limb Feedback Robot Training Study (ZEPUAISRCT)","Feasibility, Safety and Efficacy of ZEPU-AI2, AI4, AI6 Plus and AI7A Robotic Rehabilitation Systems in Patients With Upper and Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) Stroke, with onset between 2 and 24 months prior to enrollment; (b) Incomplete spinal cord injury (ASIA Scale B, C, or D); (c) Traumatic brain injury; or (d) Orthopedic disorders affecting upper and\u002For lower limb motor function\n* Age between 18 and 60 years\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with ZEPU-AI2, AI4, AI6 Plus, and AI7A systems, as per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 24, that would compromise safe participation\n* Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score \\> 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., \\> 30°), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical devices incompatible with robotic sensors\n* Pregnancy",{"count":20,"type":21},[24],"The goal of this clinical trial is to learn whether robotic rehabilitation devices (ZEPU-AI2, AI4, AI6 Plus, and AI7A) are feasible, safe, and effective for adults with upper or lower limb motor problems. These problems can result from stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic surgery. The main questions it aims to answer are:\n\nIs robotic rehabilitation training safe and practical to deliver alongside conventional therapy? Does adding robotic-assisted therapy improve motor function, balance, gait, and independence in daily activities compared to conventional rehabilitation alone? What side effects or device-related problems, if any, occur during robotic training?\n\nThe Investigators will compare a robotic-augmented rehabilitation group to a control group receiving conventional rehabilitation alone, to see if adding robotic therapy leads to better recovery.\n\nParticipants will:\n\nReceive robotic-assisted therapy sessions three times a week for 12 weeks, each lasting about 45 minutes (robotic group), or continue with conventional rehabilitation alone (control group) Undergo assessments of movement, balance, walking ability, and daily function before and after the study period Be monitored for any side effects or complications related to the device or training",[27,59,60,61,62],"Spinal Cord Injuries","Brain Injuries, Traumatic","Movement Disorder, Upper Extremity","Movement Disorder, Lower Extremity",[33,64,65,66,67,34,68],"ZEPU-AI2","ZEPU-AI4","ZEPU-AI6 Plus","ZEPU-AI7A","Musculoskeletal Rehabilitation","2026-08-04",{"date":36,"type":39},{"date":41,"type":21},{"date":73,"type":21},"2026-11",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":100,"locationsCount":47},"100650564","zepu-2000-limb-rehabilitation-trainer-study-zepu2000rct-100650564","NCT07749612","ZEPU-2000 Limb Rehabilitation Trainer Study (ZEPU2000RCT)","Feasibility, Safety and Efficacy of ZEPU-2000A, ZEPU-2000D and ZEPU-2000E Upper and Lower Limb Active and Passive Rehabilitation Trainer Systems in Patients With Upper and Lower Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following: stroke with onset between 2 and 24 months prior to enrolment; incomplete spinal cord injury (neurological level C5 and below), classified as ASIA Impairment Scale C or D; traumatic brain injury with persistent upper-limb functional limitation; or orthopedic\u002Fpost-surgical conditions involving the shoulder, elbow, wrist, or hand with persistent functional impairment for more than 3 months\n* Age between 18 and 60 years\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with ZEPU-2000A, ZEPU-2000D, and ZEPU-2000E systems, per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score less than 24, that would compromise safe participation Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score greater than 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., greater than 30 degrees), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, or presence of a pacemaker or other implanted electronic medical device incompatible with robotic sensors\n* Pregnancy",{"count":20,"type":21},[24],"The goal of this clinical trial is to learn whether the ZEPU-2000A, ZEPU-2000D and ZEPU-2000E robotic rehabilitation trainers help people with weakness or movement problems in their arms and legs. These devices are used to guide repeated arm and leg movements as part of rehabilitation therapy. The study will also look at whether the devices are safe to use.\n\nThe main questions it aims to answer are:\n\nIs training with the ZEPU-2000 devices safe, and how well do patients tolerate and stick with the training sessions? Does adding robotic training to usual rehabilitation improve muscle strength, joint movement, balance, walking, and daily function more than usual rehabilitation alone?\n\nResearchers will compare a group receiving robotic-assisted rehabilitation plus usual care to a group receiving usual rehabilitation care alone, to see whether the robotic devices provide added benefit.\n\nParticipants will:\n\nBe adults aged 18-60 with arm and\u002For leg movement problems caused by stroke, incomplete spinal cord injury, traumatic brain injury, or an orthopedic condition Attend training sessions 3 times a week for 12 weeks (about 36 sessions total), each lasting approximately 45 minutes Undergo assessments of strength, movement, balance, and daily function at the start of the study and every 2 weeks throughout the 12-week period Be monitored for any side effects or safety concerns, such as skin irritation, falls, or discomfort, at every session",[27,86,87,88,89],"Incomplete Spinal Cord Injury (SCI)","Traumatic Brain Injury","Upper Extremity Motor Dysfunction","Lower Extremity Motor Dysfunction",[91,92,93,94,95,34,96],"Robotic rehabilitation","ZEPU-2000A","ZEPU-2000D","ZEPU-2000E","Active and passive rehabilitation","Musculoskeletal rehabilitation",{"date":36,"type":39},{"date":41,"type":21},{"date":43,"type":21},{"name":45,"class":46},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":47},"100649757","zepu-sgi1plus-hand-training-study-zepusgi1rct-100649757","NCT07739264","ZEPU-SGI1PLUS Hand Training Study (ZEPUSGI1RCT)","Feasibility, Safety and Efficacy of ZEPU-SGI1PLUS Hand Functional Comprehensive Training Systems in Patients With Upper Limb Motor Dysfunction","Inclusion Criteria:\n\n* Presence of upper-limb motor dysfunction, with or without concurrent lower-limb impairment, due to one of the following conditions: (a) stroke, with onset between 2 and 24 months prior to enrollment; (b) incomplete spinal cord injury (neurological level C5 and below), classified as ASIA Impairment Scale C or D; (c) traumatic brain injury with persistent upper-limb functional limitation; or (d) orthopedic or post-surgical conditions involving the shoulder, elbow, wrist, or hand with persistent functional impairment for \\> 3 months\n* Age between 18 and 60 years, inclusive\n* Ability to understand study procedures and follow instructions, and to provide written informed consent (or assent with guardian consent where applicable)\n* Body weight and limb anthropometry compatible with the ZEPU-SG1PLUS Hand Functional Comprehensive Training System per manufacturer specifications\n* Medically stable and cleared by a physician for robotic rehabilitation, with no active infection, uncontrolled cardiac or respiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated deep vein thrombosis\n\nExclusion Criteria:\n\n* Complete spinal cord injury or profound motor paralysis preventing safe interaction with robotic devices\n* Severe cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score \\\u003C 24, that would compromise safe participation\n* Severe spasticity of the upper limb, defined as a Modified Ashworth Scale score \\> 3\n* Unstable fractures, severe fixed joint contractures of the shoulder, elbow, wrist, or hand (e.g., \\> 30°), or severe pain limiting safe robotic training\n* Uncontrolled cardiac arrhythmia, presence of a pacemaker, or other implanted electronic medical device incompatible with robotic sensors\n* Pregnancy",{"count":20,"type":21},[24],"The goal of this pilot randomized controlled trial is to learn whether the ZEPU-SG1PLUS Hand Functional Comprehensive Training System - a robotic device used alongside standard rehabilitation - is safe, feasible, and helpful for people with upper limb (arm\u002Fhand) motor problems caused by stroke, incomplete spinal cord injury, traumatic brain injury, or orthopedic conditions.\n\nThe main questions it aims to answer are:\n\nIs robotic-assisted hand training well tolerated by patients, and can it be safely added to standard rehabilitation, with acceptable rates of device-related side effects? Does adding robotic hand training to standard rehabilitation improve arm and hand strength, range of motion, and functional ability compared with standard rehabilitation alone? Is it practical to fit this type of robotic training into everyday rehabilitation services at Bangladesh Medical University?\n\nResearchers will compare a robotic-augmented rehabilitation group to a standard-care (control) group to see whether adding robotic hand training works better than usual rehabilitation alone.\n\nParticipants will:\n\nBe randomly assigned to one of two groups: one receiving standard rehabilitation plus robotic hand training with the ZEPU-SG1PLUS device, and one receiving standard rehabilitation alone If assigned to the robotic training group, attend three training sessions per week for 12 weeks, each lasting about 30-45 minutes, at the Robotic Rehabilitation Centre, BMU Undergo assessments at the start of the study and at two-week intervals during the 12-week program and follow-up period, including tests of muscle strength, joint movement, hand function, and daily activity ability Be monitored throughout for any side effects or safety concerns related to the training",[112,27,113,87,114],"Upper Limb Motor Dysfunction","Incomplete Spinal Cord Injury","Upper Limb Orthopedic Trauma",[33,116,117,34,68],"ZEPU-SG1PLUS","Hand Function Training","2026-07-29",{"date":120,"type":39},"2026-07-31",{"date":122,"type":21},"2026-07",{"date":73,"type":21},{"name":45,"class":46},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":142,"locationsCount":47},"100649645","zepu-ai5-strength-training-study-zepuai5rct-100649645","NCT07735702","ZEPU-AI5 Strength Training Study (ZEPUAI5RCT)","Safety, Feasibility and Efficacy of ZEPU AI5 Lower Limb Muscle Strength Training and Evaluation Robot","Inclusion Criteria:\n\n* Lower-limb motor dysfunction due to one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal cord injury (neurological level T12 or below, ASIA Impairment Scale C or D), or (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment more than 3 months post-surgery\n* Age greater than 18 years and up to 60 years\n* Medically stable and able to provide informed consent\n* Able to meet device anthropometric criteria for use of the ZEPU-AI5 system\n\nExclusion Criteria:\n\n* Complete spinal cord injury with inability to bear any weight\n* Severe cognitive impairment (Mini-Mental State Examination score less than 24) preventing safe participation\n* Severe spasticity of the lower limbs (Modified Ashworth Scale greater than 3)\n* Unstable fractures, severe hip\u002Fknee contractures (greater than 30 degrees fixed flexion), or severe osteoarthritis requiring imminent surgery\n* Uncontrolled cardiac arrhythmia, pacemaker incompatibility, or any implanted electronic device incompatible with the robot's sensors\n* Pregnancy",{"count":20,"type":21},[24],"The goal of this clinical trial is to learn if robot-assisted lower-limb strength and gait training can improve safety, feasibility, and functional recovery in adults aged 18-60 years with lower-limb motor dysfunction due to stroke, incomplete spinal cord injury, or persistent gait impairment following orthopedic surgery. The main questions it aims to answer are:\n\nIs robot-assisted training using the ZEPU-AI5 device safe and well-tolerated, with an acceptable rate of device-related adverse events? Does adding ZEPU-AI5-assisted training to standard-of-care rehabilitation improve functional outcomes (such as walking distance, muscle strength, balance, and mobility) compared to standard-of-care rehabilitation alone?\n\nResearchers will compare an intervention group receiving standard-of-care rehabilitation combined with ZEPU-AI5-assisted training to a control group receiving standard-of-care rehabilitation alone, to see if the addition of robotic training leads to greater improvements in safety, functional recovery, and quality of life.\n\nParticipants will:\n\nUndergo a baseline assessment before starting the study Receive either robot-assisted training plus standard-of-care rehabilitation, or standard-of-care rehabilitation alone, three times per week for 12 weeks Complete follow-up assessments every two weeks to evaluate safety, functional outcomes, and durability of any benefits",[27,113,136],"Gait Impairment Following Orthopedic Surgery",[33,34,138],"Muscle Strength",{"date":120,"type":39},{"date":122,"type":21},{"date":73,"type":21},{"name":45,"class":46},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":161,"locationsCount":47},"100649539","zepu-ai1-gait-robot-training-study-zepuai1rct-100649539","NCT07735676","ZEPU-AI1 Gait Robot Training Study (ZEPUAI1RCT)","Feasibility, Safety and Efficacy of ZEPU AI1 Gait Training and Evaluation System Robot in Patients With Lower Limb Motor Weakness","Inclusion Criteria:\n\n* Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\>3 months post-surgery\n* Age \\>18 and ≤60 years\n* Able to provide informed consent and understand instructions\n* Weight ≤100 kg and height within device adjustable range (per manufacturer specification)\n* Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, or untreated DVT)\n\nExclusion Criteria:\n\n* Complete spinal cord injury with inability to bear any weight\n* Severe cognitive impairment (e.g., MMSE \\\u003C24) preventing safe participation\n* Severe spasticity (Modified Ashworth Scale \\>3) in lower limbs\n* Unstable fractures, severe hip\u002Fknee contractures (\\>30° fixed flexion), or severe osteoarthritis requiring imminent surgery\n* Uncontrolled cardiac arrhythmia, pacemaker incompatibility, or implanted electronic device incompatible with robot sensors\n* Pregnancy",{"count":151,"type":21},32,[24],"Walking problems caused by stroke, spinal cord injury, or orthopedic surgery are common and can seriously limit a person's independence. Robotic-assisted gait training devices, which use a computer-controlled system to help patients practice standing and walking, have shown promise in improving strength, balance, and walking ability in other countries. However, this type of technology has not yet been carefully studied in Bangladesh.\n\nThis study will test a robotic gait training and evaluation device called ZEPU-AI1 in adults aged 19 to 60 years who have difficulty walking due to stroke, incomplete spinal cord injury, or gait problems following surgery. The main goals are to find out whether using this robotic device alongside standard physical therapy is feasible (practical to carry out) and safe, and to explore whether it helps improve walking speed, balance, muscle strength, and daily function compared with standard physical therapy alone.\n\nThirty-two participants will take part. Half will receive robot-assisted gait training three times a week for 12 weeks in addition to usual rehabilitation therapy, while the other half will receive usual rehabilitation therapy alone. Participants will be assessed regularly using standard walking, balance, and strength tests over the 12-week period.\n\nThe results of this study will help doctors and researchers understand whether this robotic technology can be safely and effectively introduced into rehabilitation care in Bangladesh.",[27,155,28],"Spinal Cord Injuries (SCI)",[157,33,34],"Gait Training",{"date":120,"type":39},{"date":122,"type":21},{"date":73,"type":21},{"name":45,"class":46},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":47},"100647089","zepu-ai3-lower-limb-feedback-robot-training-study-100647089","NCT07705906","ZEPU-AI3 Lower Limb Feedback Robot Training Study","Safety, Efficacy and Feasibility of ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot","ZEPUAI3RCT","Inclusion Criteria:\n\n* • Lower-limb motor dysfunction from one of the following: (a) stroke (onset 2-24 months), (b) incomplete spinal-cord injury (neurological level T12 and below, ASIA C or D), (c) orthopedic surgery (e.g., knee\u002Fhip replacement) with persistent gait impairment \\> 3month post-surgery. Stroke onset between 2-24 months ensures inclusion of individuals in the subacute to chronic phase, where gait recovery is still achievable and measurable. Incomplete SCI targets individuals with partial motor preservation, who are capable of engaging in active gait training with robotic assistance.\n\n  * Age \\>18 and ≤ 60 years. This age limit is chosen because individuals with this age range generally have better cardiopulmonary reserve and musculoskeletal tolerance, allowing safer participation in intensive robotic-assisted training with reduced risk of adverse events. Excluding younger patients minimizes heterogeneity related to growth, neurodevelopmental factors and congenital disorders, which may influence gait mechanics and response to robotic therapy. Excluding older adults (\\>60 years) helps reduce confounding from age-related degenerative changes that may affect gait outcomes and safety.\n  * Able to provide informed consent and understand instructions which ensures participants can actively engage in therapy, follow safety instructions and report adverse events.\n  * Weight ≤ 100 kg (as per device spec) and height within device adjustable range (manufacturer spec). Exceeding weight or height limits may compromise mechanical support, safety, and accurate gait training.\n  * Medically stable and cleared by physician for exoskeleton use (no active infection, uncontrolled cardiac\u002Frespiratory disease, severe osteoporosis, uncontrolled epilepsy, untreated DVT) through pre-screening with necessary investigations.\n\nExclusion Criteria:\n\n* • Complete spinal cord injury with inability to bear any weight as it requires the patient to actively support some body weight or participate in stepping movements.\n\n  * Severe cognitive impairment (e.g., MMSE \\\u003C 24) preventing safe participation.\n  * Severe spasticity (Modified Ashworth Scale \\> 3) in lower limbs. High muscle tone or rigidity increases risk of joint strain, skin injury and falls during robotic-assisted training.\n  * Unstable fractures, severe hip\u002Fknee contractures (\\> 30° fixed flexion), severe osteoarthritis requiring imminent surgery. They can pose high risk for injury during weight-bearing or gait cycles.\n  * Uncontrolled cardiac arrhythmia, pacemaker incompatibility or implanted electronic device incompatible with robot sensors. Individuals with these conditions may face elevated risk of adverse cardiac events or device malfunction.\n  * Pregnancy as safety data for robotic exoskeleton use in pregnant individuals are lacking.","70 Years",{"count":151,"type":21},[24],"Lower limb motor dysfunction resulting from stroke, spinal cord injury, or other neurological disorders substantially limits mobility, independence, and quality of life. Robotic rehabilitation has emerged as a promising approach to provide intensive, repetitive, task-oriented training. The ZEPU-AI3 Lower Limb Feedback Training and Evaluation Robot is designed to deliver interactive lower limb training while providing real-time performance feedback. This pilot randomized controlled trial aims to evaluate the safety, efficacy, and feasibility of ZEPU-AI3-assisted rehabilitation combined with conventional rehabilitation compared with conventional rehabilitation alone in patients with lower limb motor dysfunction. The primary outcomes include safety, feasibility, and changes in lower limb motor function, gait performance, and functional mobility. The findings will provide preliminary evidence to support future large-scale clinical trials and the implementation of robotic rehabilitation in clinical practice.",[27,59,175],"Gait Disorders",[33,34,177],"Feedback Training","2026-07-26",{"date":180,"type":39},"2026-07-28",{"date":182,"type":21},"2026-07-15",{"date":184,"type":21},"2026-11-15",{"name":45,"class":46},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":193,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":47},"100646231","prevalence-of-functional-dyspepsia-in-a-rural-community-of-bangladesh--a-cross-sectional-study-100646231","NCT07694778","Prevalence of Functional Dyspepsia in a Rural Community of Bangladesh : A Cross Sectional Study","Prevalence of Functional Dyspepsia in Rural Community of Bangladesh: A Cross Sectional Study","Inclusion Criteria:\n\n* Age 18 years or above\n* Resident of the selected community\n\nExclusion Criteria:\n\n* Known diagnosis of organic GI diseases.(e.g., Peptic ulcer disease, Inflammatory Bowel Disease, celiac disease, Malignancy, Intestinal Tuberculosis)\n* Severe cognitive impairment, or critical illness\n* Individuals with a history of major abdominal surgery\n* Pregnant women",true,{"count":195,"type":21},730,"OBSERVATIONAL","Functional dyspepsia (FD) is a common gastrointestinal disorder with an important impact on quality of life. There is a paucity of updated data on the prevalence of FD in rural areas of Bangladesh. The present study will be carried out to find the prevalence of FD in a community in rural Bangladesh. It also assesses potential risk factors. Eligible participants will first be evaluated for symptoms by a clinical interview using the standardized Rome IV functional dyspepsia questionnaire. Those who meet Rome IV criteria will then have an upper gastrointestinal endoscopy to exclude underlying organic diseases to establish a definitive diagnosis. Eventually patients with normal endoscopic findings will be diagnosed as having functional dyspepsia. This allows the accurate calculation of disease prevalence. Researchers will gather demographic information, lifestyle habits, and dietary patterns. The results will give important baseline data on rural FD burdens. Such data can inform community health care interventions.",[199],"Functional Dyspepsia","RECRUITING","2026-07-05",{"date":203,"type":39},"2026-07-10",{"date":205,"type":39},"2026-01-10",{"date":43,"type":21},{"name":45,"class":46},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":47},"100646822","efficacy-and-safety-of-finerenone-compared-to-spironolactone-in-treatment-of-primary-aldosteronism-100646822","NCT07688928","Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism","Inclusion Criteria:\n\n1. Age \\>18 years.\n2. History of hypertension (blood pressure \\>140\u002F90 mm Hg), both newly detected and already established patients.\n3. Diagnosed case of primary aldosteronism (PA) based on a screening test (increased aldosterone renin ration (ARR) \\>70pmol\u002FL) and confirmed by saline suppression test (post-saline PAC \\>170pmol\u002FL, where PAC measured by immunoassay).\n4. Serum potassium ≥2.5 mmol\u002FL.\n\nExclusion Criteria:\n\n1. Uncontrolled hypertension (\\>180\u002F120 mm Hg).\n2. Lateralized PA patients (aldosterone producing adenoma or unilateral hyperplasia) who want to undergo adrenalectomy or having aldosterone producing carcinoma.\n3. Participants already with mineralocorticoid receptor antagonist treatment.\n4. Patients receiving medications confounding PAC or PRC (glucocorticoids, sodium glucose co-transporter 2 inhibitors (SGLT-2i) or systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g. itraconazole, clarithromycin, rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz) that cannot be discontinued 14 days prior to randomization or for the duration of treatment period.\n5. Abnormal renal function test: eGFR \\\u003C60 ml\u002Fmin-1.73m2.\n6. Serum potassium level \\>5 mmol\u002FL.\n7. Recent cardiovascular events like acute myocardial ischemia, heart failure with hospitalization, stroke or transient ischemic attack ≤3 months before the screening visit.\n8. Uncontrolled DM (HbA1C \\>12%)\n9. Hepatic insufficiency (Child-Pugh C)\n10. Addison's disease\n11. Pregnant and lactating women. Women with child bearing potential must agree to use adequate contraception during and until 2 month of the end of study period.\n12. Patient with other form of secondary HTN (e.g. renovascular HTN, Cushing syndrome, pheochromocytoma, coarctation of aorta etc.)\n13. Known hypersensitivity to the study drugs.\n14. Patients unwilling to participate in this study",{"count":215,"type":21},104,[24],"The goal of this study is to compare the efficacy and safety of finerenone versus spironolactone in the treatment of hypertension due to primary aldosteronism.\n\nIt will be a randomized, double-blind, active-controlled, parallel-group clinical trial conducted at the Endocrine Hypertension Clinic, Department of Endocrinology, BSMMU. A total of 104 adult patients with confirmed primary aldosteronism will be enrolled and randomized equally to receive either finerenone (10-40 mg\u002Fday) or spironolactone (25-100mg\u002Fday) for 48 weeks. Study drugs will be titrated to achieve target blood pressure (\\\u003C140\u002F90mmHg) and unsuppressed plasma renin concentration (\\>15 mU\u002FL). The primary efficacy outcome will be the time and daily dose required to attain this composite endpoint. Secondary outcomes include changes in clinic and ambulatory blood pressure, plasma aldosterone and renin levels, renal function (eGFR), urinary albumin excretion, left ventricular mass index, and quality of life. Safety outcomes will include adverse events, particularly hyperkalaemia and deterioration of renal function.",[219,220],"Primary Aldosteronism","Endocrine Hypertension",[219,222,223],"Finerenone","Spironolactone","2026-06-30",{"date":226,"type":39},"2026-07-07",{"date":228,"type":39},"2026-04-15",{"date":230,"type":21},"2027-09",{"name":45,"class":46},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":47},"100642090","coeliac-plexus-vs-splanchnic-nerve-neurolysis-for-upper-abdominal-cancer-pain-100642090","NCT07653906","Coeliac Plexus vs Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain","Effect of Coeliac Plexus Versus Splanchnic Nerve Neurolysis in Pain Management With Upper Abdominal Malignancies","Inclusion Criteria:\n\n* Adult patient\n* Both genders\n* Diagnosed case of upper abdominal malignancy (pancreatic, gastric, hepatic, or biliary origin)\n* Experiencing moderate to severe pain (≥5 on a 10 point visual analog scale)\n* Patients who are conscious and can communicate\n* No Contraindication for nerve block (e.g., coagulopathy, anticoagulant drugs)\n\nExclusion Criteria:\n\n* Previous coeliac plexus block, splanchnic nerve block, or major abdominal nerve ablation\n* Severe spinal deformities or anatomical distortion at the coeliac plexus or splanchnic nerve site\n* Local or systemic infection at or near the block site\n* Known allergy to local anesthetics or neurolytic agents\n* Pregnancy\n* Lactating mother\n* Cognitive impairment or psychiatric illness",{"count":240,"type":21},44,[24],"The goal of this clinical trial is to determine whether Neurolytic Splanchnic Nerve Block (NSNB) reduces pain in adults with upper abdominal malignancies. It will also evaluate the safety of Neurolytic Splanchnic Nerve Block (NSNB). The main questions it aims to answer are:\n\nDoes NSNB reduce pain intensity compared to Neurolytic Coeliac Plexus Block (NCPB), as measured by the Visual Analog Scale (VAS)? What adverse effects do participants experience when receiving Neurolytic Splanchnic Nerve Block (NSNB)?\n\nInvestigators will compare Neurolytic Splanchnic Nerve Block (NSNB) with Neurolytic Coeliac Plexus Block (NCPB) to determine which intervention provides more effective and safer pain relief.\n\nParticipants will:\n\n* receive either NSNB or NCPB under fluoroscopic guidance\n* be monitored immediately and for 2 hours after the procedure for any complications Have their pain intensity recorded immediately after the procedure, and at 7 days, 1 month, and 3 months\n* be evaluated for quality-of-life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 3 (EORTC QLQ-C30) at 1 month and 3 months.\n* have their opioid consumption tracked throughout the study.",[244,245,246],"Abdominal Neoplasms","Pain Management","Neurolytic Techniques",[248,249,250,251],"Upper abdominal cancer","Splanchnic nerve block","Coeliac plexus block","Analgesic efficacy","2026-06-12",{"date":254,"type":39},"2026-06-17",{"date":256,"type":39},"2026-05-01",{"date":258,"type":21},"2027-01-31",{"name":45,"class":46},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":276,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100636021","efficacy-of-ultrasound-guided-erector-spinae-block-for-postoperative-pain-management-in-nephrectomy-100636021","NCT07560267","Efficacy of Ultrasound-Guided Erector Spinae Block for Postoperative Pain Management in Nephrectomy","Efficacy of Ultrasound-Guided Erector Spinae Plane Block in Postoperative Pain Management in Nephrectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 18 to 64 years\n* Scheduled for open nephrectomy (radical or partial) under general anesthesia\n* ASA physical status I-II (American Society of Anesthesiologists classification)\n\nExclusion Criteria:\n\n* Allergy to local anesthetics.\n* Local infection or inflammation at the site of the Block placement.\n* Presence of anatomical deformities in the spine\n* Coagulopathy or any bleeding disorder.\n* Pregnancy or breastfeeding women.\n* History of severe chronic pain syndrome","64 Years",{"count":269,"type":21},66,[24],"This clinical trial aims to evaluate the effectiveness of the ultrasound-guided erector spinae plane (ESP) block in managing postoperative pain for patients undergoing open nephrectomy (kidney removal surgery). The study will compare this new technique to traditional pain management methods, such as opioid medications, to assess whether the ESP block reduces pain and the need for opioids after surgery.\n\nPatients will be randomly assigned to one of two groups:\n\nGroup C will receive conventional pain relief methods, including opioids. Group E will receive the ultrasound-guided ESP block in addition to general anesthesia.\n\nThe main goals are to determine:\n\nHow much pain relief each method provides, measured using a visual analog scale (VAS).\n\nThe total amount of opioids required during the first 24 hours post-surgery.\n\nAdditional measurements will include monitoring vital signs like heart rate, blood pressure, and oxygen levels.\n\nThis study will help find safer and more effective ways to manage pain after nephrectomy, reducing the reliance on opioids and improving patient recovery",[273,274,275],"Erector Spinae Plane Block","Nephrectomy","Postoperative Pain",[277,278,279,274],"Erector Spinae Plane Block (ESP)","Postoperative Pain Management","Opioid Consumption","2026-04-24",{"date":256,"type":39},{"date":283,"type":39},"2025-09-01",{"date":285,"type":21},"2026-07-30",{"name":45,"class":46},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":267,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100631127","effect-of-scalp-block-on-intraoperative-hemodynamics-and-postoperative-pain-in-craniotomy-patients-100631127","NCT07496632","Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients\"","Efficacy of Scalp Block on Intraoperative Hemodynamic Responses and Postoperative Analgesia in Patients Undergoing Craniotomy","Inclusion Criteria:\n\n* Age 18-64 years.\n* ASA (American Society of Anesthesiologists) physical status I or II.\n* Patients scheduled for elective supratentorial craniotomy.\n* BMI of 18 to 30 kg\u002Fm².\n* GCS score of 9 to 15.\n\nExclusion Criteria:\n\n* Patient with instable blood pressure and heart rate.\n* Known allergy or hypersensitivity to local anesthetics.\n* Coagulation disorders or current anticoagulant therapy.\n* Infection at the injection site or systemic infection.\n* Patients with open skull defects.",{"count":295,"type":21},72,[24],"The goal of this clinical trial is to learn if an ultrasound-guided scalp block can improve intraoperative hemodynamic stability and provide better postoperative pain relief in adult patients undergoing elective supratentorial craniotomy. The main questions it aims to answer are:\n\nDoes ultrasound-guided scalp block reduce changes in heart rate and blood pressure during surgery compared with surgical site infiltration?\n\nDoes ultrasound-guided scalp block decrease postoperative pain and opioid requirements in the first 24 hours after craniotomy?\n\nResearchers will compare patients receiving an ultrasound-guided scalp block to those receiving standard surgical site infiltration to see if the scalp block provides better perioperative hemodynamic control and postoperative analgesia.\n\nParticipants will:\n\nReceive general anesthesia with either ultrasound-guided scalp block or surgical site infiltration\n\nHave heart rate, blood pressure, and other hemodynamic parameters monitored throughout surgery\n\nReceive standard postoperative pain management, with pain scores recorded at 0, 2, 6, 12, and 24 hours\n\nReceive opioids as needed based on pain scores, with total opioid consumption and time to first analgesic dose recorded\n\nBe monitored for adverse events, including nausea, vomiting, sedation, and block-related complications",[299],"Scalp Block",[299,301,302,303],"Intraoperative Hemodynamic Responses","Postoperative Analgesia","Craniotomy","2026-03-27",{"date":306,"type":39},"2026-04-01",{"date":308,"type":21},"2026-04",{"date":310,"type":21},"2026-10",{"name":45,"class":46},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":267,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":335,"locationsCount":47},"100629922","comparison-of-platelet-rich-plasma-and-prolotherapy-for-plantar-fasciitis-100629922","NCT07480967","Comparison of Platelet-Rich Plasma and Prolotherapy for Plantar Fasciitis","Efficacy Of Platelet Rich Plasma Therapy Versus Prolotherapy In Patients With Plantar Fasciitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient with plantar fasciitis not responding to conservative therapy.\n\nExclusion Criteria:\n\n* Patients with uncontrolled diabetes, haematological disorders, hepatitis B or C, HIV, clinical signs of acute inflammation, or septicaemia.\n\n  * Those receiving local steroid injections within one month.\n  * Those receiving non-steroidal anti-inflammatory medications within 72 hours.\n  * Platelet levels 25% below the normal level.\n  * Patient who had acute ankle or foot trauma, a diagnosis of calcaneal fracture, or stress fracture.",{"count":320,"type":21},68,[24],"This randomized controlled trial evaluates the comparative effectiveness of platelet-rich plasma (PRP) therapy and prolotherapy in patients with plantar fasciitis. Both interventions are commonly used regenerative injection therapies intended to improve pain and functional outcomes in patients who do not respond adequately to conventional conservative treatments.\n\nParticipants diagnosed with plantar fasciitis will be randomly assigned to receive either PRP injection or prolotherapy. The results of this study aim to identify the more effective injection therapy for improving clinical outcomes in patients with plantar fasciitis",[324],"Planter Fasciitis",[326,327,328],"Planter fasciitis","Prolotherapy","Platelet Rich Plasma","2026-03-18",{"date":331,"type":39},"2026-03-20",{"date":306,"type":21},{"date":334,"type":21},"2027-02-28",{"name":45,"class":46},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":343,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":47},"100627653","phase-4-efficacy-and-safety-of-mirogabalin-in-diabetic-peripheral-neuropathic-pain-100627653","NCT07451431","Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain","Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain","Inclusion Criteria:\n\n* Adults (≥40 years) with diabetic neuropathy (Toronto score ≥6).\n* Persistent pain (NPS) despite standard therapy.\n* Stable diabetes management (HbA1c ≤8.5%).\n\nExclusion Criteria:\n\n* History of drug allergy to gabapentinoids.\n* Concurrent use of opioids or other neuropathic pain medications.\n* Pregnancy or lactation.\n* Cancer pain\n* Entraptment Radioculopathy","40 Years",{"count":345,"type":21},78,[347],"PHASE4","The goal of this clinical trial is to learn if drug Mirogabalin works to treat diabetic peripheral neuropathic pain in adults. It will also learn about the safety of the drug Mirogabalin. The main questions it aims to answer are:\n\nDoes drug mirogabalin reduce neuropathic pain intensity? Is the drug mirogabalin safe in patients with diabetes suffering from neuropathic pain? Does drug mirogabalin improve patients' quality of life (QoL) ( physical, mental, and social well-being)? Researchers will compare drug mirogabalin to drug pregabalin (a drug conventionally used to treat diabetic neuropathic pain) to see if drug mirogabalin works to treat, safe and improve quality of life (QoL) in diabetic neuropathic pain.\n\nParticipants will:\n\nTake drug Mirogabalin or pregabalin every day for 8 weeks Visit the clinic at 1, 2, 4, 6, 8 weeks for checkups",[350],"Diabetic Peripheral Neuropathic Pain (DPNP)",[352,353,354,355],"Mirogabalin","Diabetic Peripheral Neuropathic Pain","Safety","Efficacy","2026-03-06",{"date":358,"type":39},"2026-03-09",{"date":360,"type":39},"2025-10-01",{"date":362,"type":21},"2027-05",{"name":45,"class":46},{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":193,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":4},"100625772","community-hypertension-control-using-the-health-belief-model-and-precede-proceed-100625772","NCT07426978","Community Hypertension Control Using the Health Belief Model and PRECEDE-PROCEED","Application of the Health Belief Model Using the PRECEDE-PROCEED Framework for Community-Based Hypertension Control: A Cluster Randomized Trial","HBM-HTN-CRT","Inclusion Criteria:\n\n* Are aged 18 years or older.\n* Have physician-diagnosed hypertension or documented systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on at least two screening occasions.\n* Have resided in the cluster for at least 6 months and plan to remain during the study period.\n* Are able to provide informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment, serious comorbidities requiring intensive care (such as advanced cancer or end-stage renal disease), and current pregnancy or intention to become pregnant within 12 months.",{"count":373,"type":21},480,[24],"This protocol describes a community-based cluster randomized controlled trial in Kamalgonj Upazila, Moulvibazar district, Bangladesh, evaluating a theory-driven intervention to improve blood pressure (BP) control among adults with hypertension. The intervention is grounded in the Health Belief Model (HBM) and structured using the PRECEDE-PROCEED framework to address behavioural and structural barriers such as poor medication adherence, high salt intake, physical inactivity, inadequate fruit intake, tobacco use, fragmented care and limited access to affordable medicines.\n\nFormative mixed-methods research in the study communities showed high levels of uncontrolled hypertension despite treatment, frequent non-adherence, unhealthy diet and activity patterns, heavy smokeless tobacco use and reliance on informal providers. These findings informed the PRECEDE phases (social, epidemiological, behavioural\u002Fenvironmental, educational\u002Fecological and administrative\u002Fpolicy assessments) and the selection of intervention targets.\n\nTwelve clusters (villages or wards of about 3,000-5,000 residents) will be randomised 1:1 to intervention or control, with around 40 participants per cluster (≈480 in total). Adults are eligible if they are ≥18 years, have physician-diagnosed hypertension or BP ≥140\u002F90 mmHg on two occasions, have lived in the cluster ≥6 months and can provide informed consent; exclusions include severe comorbidities requiring intensive care, severe cognitive impairment and pregnancy or planned pregnancy within 12 months. Randomisation is stratified by urban\u002Frural status and performed by an independent statistician, with outcome assessors and data analysts blinded where feasible. The sample size was calculated to detect a 5-7 mmHg difference in mean systolic BP at 12 months with 80% power, assuming a standard deviation of 20 mmHg, intracluster correlation of 0.02-0.05 and up to 15% loss to follow-up.\n\nThe intervention consists of four components delivered over 12 months by trained community health workers. Group education includes four bi-weekly 45-60-minute sessions on understanding hypertension, benefits of BP control, practical medication-adherence strategies and lifestyle modification (salt reduction, physical activity, healthy eating and tobacco cessation), using interactive methods and local success stories to influence perceived threat, benefits, barriers, cues to action and self-efficacy. Individual counselling and motivational interviewing (two one-to-one sessions at weeks 4 and 8) identify personal barriers, set SMART goals and build confidence for daily self-management.\n\nEnabling strategies include community BP monitoring corners equipped with automated devices, reminder calendars with tick-boxes, pictorial Bengali leaflets on low-salt recipes and exercise, wallet cards summarising key messages, and linkages to affordable generic antihypertensives and government essential drug programmes, including collaboration with local pharmacy sellers and village doctors where feasible. Reinforcing strategies involve inviting family members to at least one group session, monthly follow-up calls or home visits from months 3-12 to provide encouragement and problem-solving, facilitation of informal peer support or walking groups, and public recognition or certificates for participants who achieve BP control or sustained behaviour change. Control clusters receive usual care without structured HBM-based education or community follow-up, and will be offered a condensed version of the intervention after 12-month follow-up.\n\nData are collected at baseline, 6 months and 12 months. Primary outcomes are change in mean systolic BP from baseline to 12 months and the proportion of participants with controlled BP (systolic \\\u003C140 mmHg and diastolic \\\u003C90 mmHg) at 12 months. Secondary outcomes include change in mean diastolic BP, BP control at 6 months, HBM construct scores, medication adherence measured with the Bangladesh Medication Adherence Scale, lifestyle behaviours (salt intake, physical activity, fruit and vegetable consumption, tobacco use), knowledge of hypertension and health-service utilisation (clinic visits, BP monitoring frequency and source of BP checks). BP is measured by trained data collectors using validated automated oscillometric devices following WHO\u002FISH guidelines, with two seated readings averaged at each visit.\n\nProcess evaluation will assess fidelity, reach, dose, acceptability and contamination using attendance registers, facilitator checklists, supervision forms, questionnaires and qualitative interviews. Impact evaluation will examine changes in HBM constructs, adherence, behaviours, knowledge and service use at 6 and 12 months, while outcome",[377],"Hypertension",[377,379,380,381],"Health Belief Model","PRECEDE-PROCEED","Bangladesh","2026-02-16",{"date":384,"type":39},"2026-02-23",{"date":386,"type":21},"2027-01",{"date":388,"type":21},"2028-01",{"name":45,"class":46},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":47},"100624374","comparison-of-response-between-combination-of-transarterial-chemoembolization-and-lenvatinib-therapy-versus-lenvatinib-monotherapy-in-patients-with-unresectable-hepatocellular-carcinoma-100624374","NCT07408804","Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 years,\n2. Hepatocellular carcinoma, confirmed by dynamic CT scan \u002F MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,\n3. At least one measurable lesion based on mRECIST criteria,\n4. ECOG performance status 0-2,\n\nExclusion Criteria:\n\n1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,\n2. Hepatocellular carcinoma with main trunk portal vein thrombosis,\n3. Child Turcotte Pugh Score 10 ( C) or more,\n4. ALBI grade 3,\n5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,\n6. Known allergy or intolerance to lenvatinib .","75 Years",{"count":398,"type":21},40,[24],"The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.",[402],"Unresectable Hepatocellular Carcinoma (HCC)","2026-02-06",{"date":405,"type":39},"2026-02-13",{"date":407,"type":39},"2025-04-08",{"date":409,"type":21},"2026-09-30",{"name":45,"class":46},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":418,"minAge":419,"maxAge":170,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":47},"100600349","effect-of-vitamin-d3-on-brain-waves-in-male-parkinsons-patients-with-low-vitamin-d-a-qeeg-study-100600349","NCT07096336","Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study","Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis","Inclusion Criteria:\n\n* Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale\n* Age: 51years to70 years\n* BMI: 18.5-24.9 kg\u002Fm2\n* Hypovitaminosis D (Serum 25(OH)D level \\\u003C30 ng\u002Fml)\n* Patients on Levodopa therapy\n\nExclusion Criteria:\n\n* Already taking vitamin D3 supplements\n* Current use of medication\u002Fsubstances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.\n* Patients who are currently suffering from following diseases\n\n  * Neurological disorders (Migraine, epilepsy)\n  * Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure)\n  * Respiratory disorders (Bronchial asthma, COPD)\n  * Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia)\n* With biochemical evidence of-\n\n  * Hypercalcemia\n  * Renal insufficiency\n  * Liver diseases\n  * Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism)\n* Active smoker","MALE","51 Years",{"count":421,"type":21},15,[24],"This is an experimental study (Interventional self-controlled trial, pretest-posttest design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male Parkinson's disease patients with hypovitaminosis D.\n\nThe main question it aims to answer is:\n\nVitamin D3 supplementation has effect on brain waves in male Parkinson's disease patients with hypovitaminosis D.\n\nResearcher will compare the effect of vitamin D3 supplementation on brain waves in male Parkinson's disease patients with hypovitaminosis D with their pre intervention ( baseline ) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG).\n\nParticipants will :\n\nTake vitamin D3 orally for 8 weeks (50,000 IU\u002Fweek) Visit the medical university after 8 weeks for evaluation of serum 25(OH)D level and QEEG Must bring the empty strips of vitamin D supplement with them during their visit.",[425],"PARKINSON DISEASE (Disorder)",[427,428,429,430,431,432,433,434,435],"Parkinson's disease","Vitamin D3","Quantitative EEG (qEEG)","Brain wave","25-hydroxyvitamin D","Spectral power","Dopaminergic neurons","EEG frequency bands","Neurodegeneration","2025-07-29",{"date":438,"type":39},"2025-07-31",{"date":440,"type":39},"2025-07-15",{"date":442,"type":21},"2025-11",{"name":45,"class":46},{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":418,"minAge":451,"maxAge":343,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":453,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":47},"100600355","effect-of-vitamin-d3-supplementation-on-brain-waves-in-male-epileptic-patients-with-hypovitaminosis-d-100600355","NCT07096414","Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D","Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D: A Quantitative Electroencephalogram Analysis","Inclusion Criteria:\n\n* Diagnosed male patients with Epilepsy by neurologist from the Out Patient Department of Department of Neurology, BMU by taking proper history of at least two unprovoked (or reflex) seizures occurring \\> 24 hours apart, from patients and eye witnesses.\n* Hypovitaminosis D (\\\u003C30 ng\u002Fml)\n* BMI : 20 - 24 kg\u002Fm²\n* On antiepileptic medication for 6 months to 2 years (enzyme inducing AEDs, e.g. Carbamazepine, Phenytoin, Phenobarbital)\n* Without any medication that affect central nervous system other than antiepileptic drugs (Antidepressants, Antipsychotic, Anxiolytic, Anesthetic drugs)\n* Apparently normal physical health\n\nExclusion Criteria:\n\n* Patients suffering from absence seizure\n* Certain AEDs (Sodium valproate, Ethosuximide, Oxcarbazepine, Topiramate, Lamotrigine, Levetiracetam)\n* Smoker\n* Alcoholic\n* Known hypersensitivity to vitamin D3\n* Patients with hypertension\n* Patient with Thyroid disorder\n* Patient with Diabetes mellitus\n* Patient with Renal Disease\n* Patient with liver Disease\n* Patient with hypercalcemia","20 Years",{"count":421,"type":21},[24],"This is an experimental study (interventional self-controlled trial, pretest-post test design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male epileptic patients with hypovitaminosis D.\n\n. The main question it aims to answer is:\n\nVitamin D3 supplementation has effect on brain waves in male epileptic patients with hypovitaminosis D.\n\nResearcher will compare the effect of Vitamin D3 supplementation on brain waves in male epileptic patients with hypovitaminosis D with their pre-intervention (baseline) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG).\n\nParticipants will:\n\nTake Vitamin D3 orally for 8 weeks (50,000IU\u002Fweek) Visit the medical university after 8 weeks for evaluation of serum 25 (OH) D level and quantitative electroencephalogram (QEEG) Must bring the empty strips of Vitamin D supplement with them during their visit",[456,457],"Epilepsy","Hypovitaminosis D",[456,428,457,459,460],"QEEG","Brainwaves","2025-07-24",{"date":438,"type":39},{"date":464,"type":39},"2025-07-19",{"date":466,"type":21},"2025-10",{"name":45,"class":46},{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":418,"minAge":451,"maxAge":343,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":47},"100599523","effect-of-vitamin-d3-supplementation-on-cardiac-autonomic-nerve-function-in-male-epileptic-patients-with-hypovitaminosis-d-100599523","NCT07085598","Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Epileptic Patients With Hypovitaminosis D","Inclusion Criteria:\n\n* • Diagnosed male patients with Epilepsy by neurologist from the OPD of Department of Neurology by taking proper history of at least two unprovoked (or reflex) seizures occuring \\> 24 hours apart, from patients and eye witnesses.\n\n  * Having hypovitaminosis D (serum vitamin D3 level \\\u003C30 ng\u002Fml)\n  * Age: 20-40 years.\n\n    * Sex: Male\n    * BMI : 18.5-24.9 kg\u002Fm2\n    * Taking antiepileptic drug for 6 months to 2 years ( Enzyme inducer AEDs, e.g. Carbamazepine, Phenytoin, Phenobarbital)\n    * Without medication that affect central nervous system other than antiepileptic drugs (AEDs).\n\nExclusion Criteria:\n\n* • Epileptic patients taking Sodium valproate, oxcarbazepine, Topiramate, Lamotrigine, Levetiracetam.\n\n  * Patient having absence seizure\n  * Alcoholic\n  * Smoker\n  * Patients taking following drugs will be excluded-\n\n    * Anti-diabetic drugs\n    * Antioxidant vitamin supplements\n    * Antihypertensive drug\n    * Anti-arrhythmic drug\n    * Lipid lowering medications\n    * Sedatives\n  * Patients having known hypersensitivity to vitamin D3\n  * All patients with the history of or currently suffering from following diseases \\& condition will be excluded-\n\n    * Cardiovascular disorders (Myocardial infarction, coronary heart disease, cardiac arrhythmia, CCF)\n    * Other neurological disorders (Migraine, stroke)\n    * Respiratory disorders (Bronchial asthma, COPD)\n    * Renal insufficiency (S. Creatinine \\> 1.5 mg\u002Fdl, Acute or chronic kidney disease)\n    * Endocrine disease (Diabetes mellitus, Thyroid disorders- hypothyroidism, hyperthyroidism)\n    * Arthritis (rheumatoid arthritis)\n    * Liver diseases\n    * Neoplastic disease\n    * Psychiatric disorder (schizophrenia, bipolar disorder)\n    * Current use of iron, zinc, calcium, magnesium and multivitamin supplementation\n    * Already performing yoga or breathing exercise\n    * Patients with hypercalcemia",{"count":421,"type":21},[24],"The goal of this clinical trial is to see the effect of vitamin D3 supplementation on cardiac autonomic nerve function in male epileptic patients with hypovitaminosis D that weather vitamin D improves heart rate variability or not. The main questions it aims to answer are:\n\n1. Does vitamin D improves cardiac autonomic tone in male epileptic patients?\n2. Does vitamin D improves heart rate variability in male epileptic patients?\n\nIt is a self control trial. Participants will:\n\n1. undergo through baseline HRV testing\n2. start to take vitamin D3 50000 IU once in a week for 8 weeks\n\nb) visit the university after 8 weeks for post interventional HRV testing . Researcher will compare the pre test and post test value of HRV testing.",[456],[428,457,479],"HRV",{"date":481,"type":39},"2025-07-25",{"date":483,"type":21},"2025-07",{"date":466,"type":21},{"name":45,"class":46},{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":418,"minAge":419,"maxAge":170,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":503,"locationsCount":47},"100599446","effect-of-vitamin-d3-supplementation-on-cardiac-autonomic-nerve-function-in-male-parkinsons-disease-patients-with-hypovitaminosis-d-100599446","NCT07084597","Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Parkinson's Disease Patients With Hypovitaminosis D","Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male","IInclusion criteria:\n\n* Male patients with of Parkinson's disease diagnosed by neurologist with unilateral or bilateral involvement and mild to moderate disability according to Hoehn and Yahr (H-Y) scale (I-III)\n* Age: 51-70 years\n* BMI: 18.5-24.9 kg\u002Fm2\n* Vitamin D3 deficient or insufficient\n* On Levodopa medication\n\nExclusion criteria:\n\n1. Patients with a history of drug abuse including alcoholism.\n2. Patients on following drugs will be excluded-\n\n   * Antioxidant vitamin supplements\n   * Lipid lowering medications\n   * Antihypertensive drug\n   * Anti-arrhythmic drug\n   * Sedatives\n3. All patients with the history of or clinical manifestation of currently suffering from following diseases \\& condition will be excluded\n\n   * Severe Cardiovascular disorders\n   * Severe neurological disorders\n   * Severe Respiratory disorders\n   * Severe Renal insufficiency (S. Creatinine \\> 1.5 mg\u002Fdl, Acute or chronic kidney disease)\n   * Severe Endocrine disease\n   * Severe Arthritis\n   * Severe Liver diseases\n   * Severe Neoplastic disease\n   * Severe Psychiatric disorder\n   * Current use of iron, zinc, calcium, magnesium and multivitamin supplementation\n   * Already performing yoga or breathing exercise\n   * Hypercalcemia",{"count":421,"type":21},[24],"The goal of this clinical trial is to see the effect of vitamin D3 supplementation on cardiac autonomic nerve function in male Parkinson's disease patients with hypovitaminosis D\n\nMain questions it aims to answer are:\n\n1. Does vitamin D improves heart rate variability(HRV) in male Parkinson's disease patients ?\n2. Does vitamin D improves cardiac autonomic nerve function in male Parkinson's disease patients ? It is a self control trial. Vitamin D3 deficient Parkinson's disease participants will\n\na. undergo through baseline HRV test b. Then they will take vitamin D3 capsule 50000 IU once in a week for 8 consecutive weeks c. Then after intervention with vitamin D supplementation post interventional HRV will be done.\n\nResearcher will compare pre intervention(pre test) and post intervention(post test) value of HRV",[497],"Parkinson Disease",[428,479,457,499],"Parkinson disease",{"date":436,"type":39},{"date":483,"type":21},{"date":466,"type":21},{"name":45,"class":46},""]